Ferraz Bruna Elias Parreira Lopes, Signorini Filho Roney César, Carvalho Lucas Ribeiro Borges, Almeida Michelle Samora, Bonetti Tatiana Carvalho de Souza, Araujo Júnior Edward, Braga Antonio, Sun Sue Yazaki
Department of Obstetrics, Paulista School of Medicine, Federal University of São Paulo (EPM-UNIFESP), Rua Belchior de Azevedo, 156 apto. 111 Torre Vitoria, Vila Leopoldina, São Paulo, SP CEP 05089-030, Brazil.
Discipline of Oncology, Paulista School of Medicine, Federal University of São Paulo (EPM-UNIFESP), São Paulo, SP, Brazil.
J Gynecol Obstet Hum Reprod. 2025 Feb;54(2):102890. doi: 10.1016/j.jogoh.2024.102890. Epub 2024 Dec 9.
Cervical cancer is the third most common cancer in Brazil. Although rare, its diagnosis during pregnancy represents a great challenge for the medical team and the patient. The objective of this study was to evaluate the maternal and perinatal outcomes of pregnant women who underwent neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced stage cervical cancer.
This was a descriptive, retrospective study that included pregnant women with advanced stage cervical cancer (IB3 a IIIC1) who were treated at our center over 12 years. These patients received neoadjuvant chemotherapy with carboplatin plus paclitaxel during pregnancy to prevent disease progression.
Tumor shrinkage of at least 50 % was observed in four patients, while the disease remained stable in three others. There was one case of fetal death without apparent cause at 29 weeks, but all other mothers were discharged from the hospital at the same time as their healthy newborns.
Chemotherapy with carboplatin and paclitaxel administered to pregnant women with advanced stage cervical cancer (IB3 - IIIC1) may have prevented disease progression without worsening neonatal outcomes.
宫颈癌是巴西第三大常见癌症。尽管在孕期诊断出宫颈癌的情况较为罕见，但这对医疗团队和患者来说都是巨大的挑战。本研究的目的是评估接受卡铂和紫杉醇新辅助化疗的晚期宫颈癌孕妇的母婴及围产期结局。
这是一项描述性回顾性研究，纳入了在我们中心接受治疗超过12年的晚期宫颈癌（IB3至IIIC1期）孕妇。这些患者在孕期接受卡铂加紫杉醇新辅助化疗以防止疾病进展。
4例患者肿瘤缩小至少50%，另外3例病情保持稳定。有1例在29周时胎儿无明显原因死亡，但其他所有母亲均与健康新生儿同时出院。
对晚期宫颈癌（IB3 - IIIC1期）孕妇给予卡铂和紫杉醇化疗可能预防了疾病进展，且未使新生儿结局恶化。
